Skip to main content
Camille Bedrosian, MD, Oncology, Cambridge, MA

Camille Lucia Bedrosian MD


Physician

Join to View Full Profile
  • 26 Landsdowne StreetCambridge, MA 02139

  • Phone+1 617-494-0400

  • Fax+1 617-494-8144

Join Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
    You already have 1 invite waiting!
  • Read the latest clinical news, personalized to your specialty.

Summary

  • Dr. Camille Bedrosian, MD is an oncologist in Cambridge, Massachusetts. She is currently licensed to practice medicine in Massachusetts and North Carolina.

Education & Training

  • Duke University Hospital
    Duke University HospitalFellowship, Hematology and Medical Oncology, 1986 - 1988
  • Duke University Hospital
    Duke University HospitalResidency, Internal Medicine, 1984 - 1986
  • Newton-Wellesley Hospital
    Newton-Wellesley HospitalInternship, Internal Medicine, 1983 - 1984
  • Harvard Medical School
    Harvard Medical SchoolClass of 1983

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 1998 - 2026
  • NC State Medical License
    NC State Medical License 1987 - 2025
  • Internal Medicine
    American Board of Internal Medicine Internal Medicine

Publications & Presentations

PubMed

Press Mentions

  • Amylyx Pharmaceuticals Announces Positive Long-Term Results from Phase 2 HELIOS Clinical Trial of AMX0035 in People with Wolfram Syndrome
    Amylyx Pharmaceuticals Announces Positive Long-Term Results from Phase 2 HELIOS Clinical Trial of AMX0035 in People with Wolfram SyndromeMay 8th, 2025
  • New Research Aims to Address Unmet Needs Following Weight Loss Surgeries
    New Research Aims to Address Unmet Needs Following Weight Loss SurgeriesMarch 4th, 2025
  • Amylyx Touts ‘Encouraging’ Phase 2 Alzheimer’s Trial Data
    Amylyx Touts ‘Encouraging’ Phase 2 Alzheimer’s Trial DataAugust 15th, 2024
  • Join now to see all